Colleagues, friends, fans across Hollywood were aghast tonight over the sudden death of Rob Reiner and his wife Michelle ...

Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. People living with thymidine kinase 2 ...

Regional banking company United Community Banks (NYSE:UCB) reported Q3 CY2025 results beating Wall Street’s revenue expectations , with sales up 12.7% year on year to $276.8 million. Its non-GAAP ...

UCB's experimental medicine for rare disease thymidine kinase 2 deficiency (TK2d) has been shown to reduce the risk of death by a massive 95% in a study, as marketing applications are reviewed in the ...

Shares in Belgium’s UCB SA soared to a record, while rival MoonLake Immunotherapeutics lost most of its value, after the latter announced late-stage trial data for an experimental skin disease drug ...

Investing.com -- Shares of UCB S.A. jumped more than 16% Monday after data showed its hidradenitis suppurativa treatment, Bimzelx, outperformed competitor MoonLake’s sonelokimab in Phase 3 trials, ...

If you have been following UCB (ENXTBR:UCB), the recent moves in its share price have probably caught your eye. After an extended period of subdued trading, investors are starting to wonder if ...

BRUSSELS, Aug. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy Congress (IEC) ...

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study ...

Parkinson’s disease (PD) is a neurodegenerative disease of the central nervous system characterized by the loss of dopaminergic neurons in the substantia nigra and the abnormal aggregation of ...

UCB SA's solid buy case is driven by Bimzelx's impressive performance and robust financials despite a temporary 19% EBITDA decline due to product launch investments. Bimzelx, approved for psoriasis ...